[Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
Bartsch
G
G
Abteilung für Urologie und Kinderurologie, Urologische Universitätsklinik und Poliklinik Ulm, Prittwitzstrasse 43, 89075 Ulm. georg.bartsch@uniklinik-ulm.de
Eggert
K
K
Soker
S
S
Fiedler
W
W
Laack
E
E
Volkmer
B G
BG
Gschwend
J
J
Bokemeyer
C
C
Hautmann
R
R
Schuch
G
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D043168:Angiostatins / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000098:blood supply* / Q000188:drug therapy* / Q000532:radiotherapy; D043169:Endostatins / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000532:radiotherapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins; D011993:Recombinant Fusion Proteins; D043168:Angiostatins